Xanomeline

Major

Xanomeline Sertraline Explained Increased CYP2D6 substrate exposure Details

Moderate

Xanomeline Colchicine Colcrys Explained Increased oral P-gp substrate with NTI exposure and an increased risk on severity and frequency of oral P-gp substrate with NTI-re... Details Xanomeline Simvastatin Flolipid Explained Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Xanomeline Abemaciclib Verzenio Explained Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Xanomeline Acalabrutinib Calquence Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Xanomeline Avapritinib Ayvakit Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Xanomeline Aclidinium Oral Inhalation Tudorza An increased risk of anticholinergic adverse reactions (eg, dry mouth, constipation) Details Xanomeline Avanafil Stendra Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Xanomeline Atropine Ophthalmic Atropine Care 1% An increased risk of anticholinergic adverse reactions (eg, dry mouth, constipation) Details Xanomeline Bosutinib Bosulif Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Xanomeline Budesonide Entocort Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Xanomeline Budesonide Nasal Spray Rhinocort Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Xanomeline Budesonide Oral Inhalation Pulmicort Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Xanomeline Cyclopentolate Ophthalmic Akpentolate® An increased risk of anticholinergic adverse reactions (eg, dry mouth, constipation) Details Xanomeline Cyclosporine Injection Atopica Increased oral sensitive CYP3A4 substrate that are P-gp substrates with NTI exposure and an increased risk on severity and frequen... Details Xanomeline Cyclosporine Ophthalmic Cequa Increased oral sensitive CYP3A4 substrate that are P-gp substrates with NTI exposure and an increased risk on severity and frequen... Details Xanomeline Dacomitinib Vizimpro Increased xanomeline exposure and an increased risk on severity and frequency of xanomeline-related adverse reactions Details Xanomeline Dasatinib Phyrago Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Xanomeline Digoxin Cardoxin® Increased oral P-gp substrate with NTI exposure and an increased risk on severity and frequency of oral P-gp substrate with NTI-re... Details Xanomeline Everolimus Afinitor Increased oral sensitive CYP3A4 substrate that are P-gp substrates with NTI exposure and an increased risk on severity and frequen... Details Xanomeline Felodipine Plendil® Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Xanomeline Finerenone Kerendia Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Xanomeline Glycopyrronium Topical Cuvposa® An increased risk of anticholinergic adverse reactions (eg, dry mouth, constipation) Details Xanomeline Ibrutinib Imbruvica Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Xanomeline Ivabradine Corlanor Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Xanomeline Lovastatin Altocor® Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Xanomeline Lurasidone Latuda Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Xanomeline Maraviroc Selzentry Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Xanomeline Midazolam Nasal Spray Nayzilam Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Xanomeline Midazolam Injection Nayzilam Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Xanomeline Midostaurin Rydapt Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Xanomeline Naloxegol Movantik Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Xanomeline Nisoldipine Sular Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details